Daivobet is a drug used to treat skin diseases.
Release form and composition
Daivobet is produced in the form of a uniform white ointment, in aluminum tubes of 15, 30 and 60 g.
The composition of one gram of agent includes 643 μg of betamethasone dipropionate, 52 μg of calcipotriol monohydrate and excipients — soft white paraffin, α-tocopherol, liquid paraffin and polyoxypropylene-15-stearyl ether.
Indications for use
Daivobet is used to treat chronic vulvar plaque psoriasis.
The use of Daivobet is contraindicated in case of hypersensitivity to the components included in its composition, as well as in the following cases:
- Perianal and genital itching;
- Diseases associated with impaired calcium metabolism;
- Severe renal and hepatic insufficiency;
- Viral, fungal, parasitic and bacterial infections of the skin;
- Atrophy and ulcers of the skin;
- Pink and acne vulgaris;
- Perioral dermatitis;
- Drop-shaped, exfoliative and pustular psoriasis;
- Skin manifestations of tuberculosis and syphilis;
- Psoriatic erythroderma;
- Increased fragility of skin vessels.
The use of Daivobet during pregnancy and during the period of breastfeeding is possible only in cases when the expected effect of the therapy outweighs the possible risk to the developing fetus and infant.
Dosing and Administration
The ointment is applied externally, applying a thin layer of the agent to the affected areas of the skin once a day. The maximum daily dose of Daivobet is 15 g, weekly - 100 g. The average duration of therapy is 28 days, with the possible repetition of the course prescribed by a doctor.
Daivobet can not be applied to large areas of skin (more than 30% of the body surface).
The instructions for Daivochet indicate that the drug may cause side effects from the skin and skin appendages, namely:
- Pustular psoriasis;
- Burning sensation;
- Violation of pigmentation at the site of application of the ointment;
- Exacerbation of psoriasis;
In rare cases, with the use of Daivobet, hypercalciuria and hypercalcemia occur.
Symptoms of an overdose of the drug are an increase in blood calcium, as well as suppression of the function of the pituitary-adrenal system, against the background of which a reversible secondary adrenal insufficiency develops.
In such cases, it requires the cancellation of Daivobet and the appointment of symptomatic therapy. It is important for patients with chronic toxicity to gradually discontinue the drug.
Ointment should not be applied to the scalp, face skin and mucous membranes. After applying Daivobet, hands should be washed thoroughly with soap and water.
The simultaneous use of drugs with other glucocorticosteroids is not recommended.
At observance of the recommendations concerning dosage of means, the risk of development of a hypercalcemia is minimum. If Daivobet is used in doses higher than recommended, the concentration of calcium in the blood plasma may increase. In such cases, hypercalcemia quickly passes with a decrease in dose or withdrawal of the drug.
It should be borne in mind that the application of ointment on large areas of skin (more than 30% of the body), in skin folds and under the occlusive dressing significantly increases the risk of systemic adverse reactions.
It is recommended to avoid direct sunlight or UV radiation during the period of Daivobate therapy.
The drug is synonymous with Xamiol. The analogues of Daivobet include Silkis, Ammifurin, Beroxan and Glenriaz.
Terms and conditions of storage
In accordance with the instructions, Daivobt should be stored in a dark, dry and out of reach of children, at a temperature not exceeding 25 ° C.
Pharmacies dispensed over-the-counter medicine. The shelf life of ointment, subject to the recommendations of the manufacturer, is two years. After opening the tube, the drug must be used within 3 months.